MATINAS BIOPHARMA HOLDINGS, INC. Deferred State and Local Income Tax Expense (Benefit)
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Deferred State and Local Income Tax Expense (Benefit) of $35.30 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2019-04-01.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2019-04-01
- MATINAS BIOPHARMA HOLDINGS, INC. deferred state and local income tax expense (benefit) for fiscal 2017 was $35.30K.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month |
|---|---|
| 2017-12-31 | $35.30K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |